secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001104659-26-018371
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyprium (Fortress subsidiary) sells PRV for $205M cash; Oaktree loan covenants eased
--------------------------------------------------------------------------------

- Cyprium Therapeutics, 80.4% owned by Fortress, agreed to sell a Rare Pediatric Disease Priority Review Voucher for $205M cash.
- Fortress expects to receive at least $100M from Cyprium via dividends and intercompany payments after closing.
- Second Amendment to Oaktree loan: mandatory $10M prepayment upon PRV proceeds; if loan ≤$10M, key financial covenants removed.
- PRV issued after FDA approval of ZYCUBO (copper histidinate) for Menkes disease in Jan 2026; 20% of proceeds owed to NIH.
- Cyprium still eligible for up to $129M in development/sales milestones and royalties from Sentynl on ZYCUBO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926018371/0001104659-26-018371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926018371/fbio-20260222x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer